https://www.selleckchem.com/pr....oducts/itacnosertib.
We assessed real-world spectrum and patterns of irAEs for patients treated with anti-PD(L)1 ICIs. irAEs were defined using medical and pharmacy claims for patients enrolled in a Medicare Advantage Prescription Drug plan who initiated treatment with anti-PD(L)-1 and received ≥1 dose of therapy between September 1, 2014 and February 28, 2018. Treatment was discontinued for 46.6% of patients, and withheld and subsequently restarted for 10.3%. While toxicity profiles did not differ by age, RiskRx-V co-morbidity index was higher in pati
Like
Comment
Share
